KMDA | tickerfilter.com

Fundamental analysis

49%

Profitability 58%

Dept financing 5%

Liquidity 75%

Performance 44%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.78%

1 Month

7.00%

3 Months

31.65%

6 Months

22.71%

1 Year

25.14%

2 Year

46.45%

Key data

Stock price

$8.86

P/E Ratio

0.00

DAY RANGE

$8.80 - $9.10

EPS

$0.57

52 WEEK RANGE

$5.54 - $9.35

52 WEEK CHANGE

$25.14

MARKET CAP

330.474 M

YIELD

N/A

SHARES OUTSTANDING

57.474 M

DIVIDEND

$0.20

EX-DIVIDEND DATE

03-17-2025

NEXT EARNINGS DATE

05-07-2025

BETA

0.49

PUBLIC FLOAT

AVERAGE 10 VOLUME

$57,590

AVERAGE 30 VOLUME

$71,113

Company detail

CEO: Amir London
Region: US
Website: kamada.com
Employees: 360
IPO year: 2010

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to AATD. It also provides Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity.

KMDA - KAMADA LTD